MARKET

EPZM

EPZM

Epizyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5022
-0.0184
-3.53%
Opening 10:09 05/16 EDT
OPEN
0.5488
PREV CLOSE
0.5206
HIGH
0.5610
LOW
0.4800
VOLUME
306.09K
TURNOVER
81.23K
52 WEEK HIGH
9.86
52 WEEK LOW
0.4401
MARKET CAP
82.80M
P/E (TTM)
-0.2343
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 9h ago
30 Stocks Moving in Monday's Pre-Market Session
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) rose 25.2% to $2.09 in pre-market trading after gaining around 10% on Friday.
Benzinga · 10h ago
--HC Wainwright Adjusts Epizyme Price Target to $8 From $10, Maintains Buy Rating
MT Newswires · 4d ago
Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates
Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.
Zacks · 5d ago
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 5d ago
--Wedbush Adjusts Price Target for Epizyme to $7 From $9, Maintains Outperform Rating
MT Newswires · 6d ago
Epizyme: Q1 Earnings Insights
  Epizyme (NASDAQ:EPZM) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Benzinga · 6d ago
Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates
Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6d ago
More
No Data
Learn about the latest financial forecast of EPZM. Analyze the recent business situations of Epizyme through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
60.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average EPZM stock price target is 5.92 with a high estimate of 10.00 and a low estimate of 0.6000.
High10.00
Average5.92
Low0.6000
Current 0.5019
EPS
Actual
Estimate
-0.51-0.38-0.26-0.13
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 215
Institutional Holdings: 126.66M
% Owned: 76.86%
Shares Outstanding: 164.87M
TypeInstitutionsShares
Increased
13
26.35M
New
4
345.97K
Decreased
7
114.61K
Sold Out
10
646.45K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Non-Executive Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Grant Bogle
Chief Operating Officer
Jerald Korn
Chief Scientific Officer
Jeffery Kutok
Director
Pablo Legorreta
Independent Director
Kenneth Bate
Independent Director
Roy Beveridge
Independent Director
Kevin Conroy
Independent Director
Michael Giordano
Independent Director
Carl Goldfischer
Independent Director
Victoria Richon
Independent Director
Carol Stuckley
No Data
No Data
About EPZM
Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization epigenetic treatment for people with cancer and other serious diseases. The Company’s lead product candidate TAZVERIK (tazemetostat) is an oral selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT). AZVERIK is available to the eligible patients and their physicians in the United States through a specialty distribution network. The Company is developing tazemetostat for the treatment of a range of cancer types in multiple treatment settings. Tazemetostat is a pipeline product, which is showing clinical activity as an investigational monotherapy in multiple cancer indications.

Webull offers kinds of Epizyme Inc stock information, including NASDAQ:EPZM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPZM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EPZM stock methods without spending real money on the virtual paper trading platform.